62,634 Shares in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Purchased by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 62,634 shares of the company’s stock, valued at approximately $101,000. Point72 Asia Singapore Pte. Ltd. owned approximately 0.12% of PMV Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio boosted its stake in PMV Pharmaceuticals by 174.2% in the 1st quarter. Public Employees Retirement System of Ohio now owns 22,757 shares of the company’s stock worth $39,000 after buying an additional 14,457 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in PMV Pharmaceuticals in the 1st quarter worth about $26,000. Price T Rowe Associates Inc. MD boosted its stake in PMV Pharmaceuticals by 71.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 42,802 shares of the company’s stock worth $73,000 after buying an additional 17,858 shares during the last quarter. Aristides Capital LLC acquired a new stake in PMV Pharmaceuticals in the 4th quarter worth about $97,000. Finally, Vanguard Group Inc. boosted its stake in PMV Pharmaceuticals by 1.9% in the 1st quarter. Vanguard Group Inc. now owns 2,452,111 shares of the company’s stock worth $4,169,000 after buying an additional 46,804 shares during the last quarter. Hedge funds and other institutional investors own 90.20% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of PMV Pharmaceuticals in a research note on Tuesday, August 20th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, PMV Pharmaceuticals has an average rating of “Buy” and a consensus target price of $5.75.

PMV Pharmaceuticals Price Performance

NASDAQ PMVP opened at $1.53 on Friday. The firm has a market capitalization of $78.71 million, a P/E ratio of -1.15 and a beta of 1.52. PMV Pharmaceuticals, Inc. has a 1-year low of $1.18 and a 1-year high of $6.66. The business’s 50-day simple moving average is $1.53 and its 200-day simple moving average is $1.67.

PMV Pharmaceuticals (NASDAQ:PMVP) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.32. On average, equities research analysts expect that PMV Pharmaceuticals, Inc. will post -1.05 EPS for the current fiscal year.

PMV Pharmaceuticals Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.